The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV1/FVC Ratio in Tiotropium Safety and Performance in Respimat Participants

被引:13
作者
Calverley, Peter M. A. [1 ]
Mueller, Achim [2 ]
Fowler, Andrew [3 ]
Metzdorf, Norbert [4 ]
Wise, Robert A. [5 ]
机构
[1] Univ Liverpool, Inst Ageing & Chron Dis, Clin Sci Ctr, Liverpool, Merseyside, England
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[3] Boehringer Ingelheim Pharma Ltd, Bracknell, Berks, England
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
关键词
airflow obstruction; disease exacerbation; mortality; tiotropium; THORACIC SOCIETY; FIXED-RATIO; DIAGNOSIS; COPD; THRESHOLDS; SPIROMETRY; MANAGEMENT; EQUATIONS; UPDATE; CUTOFF;
D O I
10.1513/AnnalsATS.201703-194OC
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Rationale: There is continuing debate about whether to define airflow obstruction by a post-bronchodilator ratio of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) below 0.70, or by ratio values falling below the age-dependent lower limit of normal (LLN) derived from general population data. Objectives: To determine whether using the LLN criterion affects the classification and outcomes of patients previously defined as having chronic obstructive pulmonary disease by the fixed FEV1/FVC ratio. Methods: We applied the LLN definition to pooled data from the Tiotropium Safety and Performance in Respimat study that used the fixed FEV1/FVC ratio for the clinical diagnosis of chronic obstructive pulmonary disease. Results: A total of 17,072 patients were analyzed; of these, 1,807 (10.6%) patients had a ratio greater than or equal to LLN. Patients with a ratio greater than or equal to LLN had similar risks of death from any cause and fatal major adverse cardiovascular (CV) event as those below LLN. Patients with a ratio below LLN had a significantly lower risk of major adverse CV events (hazard ratio = 0.69; 95% confidence interval [CI] = 0.55-0.86; P = 0.001), and had significantly greater risks of moderate to severe exacerbation (rate ratio = 1.48; 95% CI = 1.36-1.61; P < 0.0001) and severe exacerbation (rate ratio = 2.01; 95% CI = 1.68-2.40; P < 0.0001) when compared with patients greater than or equal to LLN. Study outcomes by treatment arm(5 mu g tiotropium Respimat vs. 18 mu g HandiHaler) were comparable. Conclusions: Using the LLN to define airflow obstruction would have excluded patients in the Tiotropium Safety and Performance in Respimat study with a higher risk of nonfatal major adverse CV events and a lower risk of exacerbation; study outcomes by treatment arm (2.5 mu g/5 mu g tiotropium Respimat vs. 18 mu g HandiHaler) remained similar.
引用
收藏
页码:200 / 208
页数:9
相关论文
共 29 条
[1]  
[Anonymous], CHRON OBSTR PULM DIS
[2]   The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes [J].
Anzueto, Antonio ;
Wise, Robert ;
Calverley, Peter ;
Dusser, Daniel ;
Tang, Wenbo ;
Metzdorf, Norbert ;
Dahl, Ronald .
RESPIRATORY RESEARCH, 2015, 16
[3]   Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction [J].
Bhatt, Surya P. ;
Sieren, Jessica C. ;
Dransfield, Mark T. ;
Washko, George R. ;
Newell, John D., Jr. ;
Stinson, Douglas S. ;
Zamba, Gideon K. D. ;
Hoffman, Eric A. .
THORAX, 2014, 69 (05) :409-414
[4]   Population impact of different definitions of airway obstruction [J].
Celli, BR ;
Halbert, RJ ;
Isonaka, S ;
Schau, B .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (02) :268-273
[5]   Underestimation of airflow obstruction among young adults using FEV1/FVC &lt;70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes [J].
Cerveri, I. ;
Corsico, A. G. ;
Accordini, S. ;
Niniano, R. ;
Ansaldo, E. ;
Anto, J. M. ;
Kunzli, N. ;
Janson, C. ;
Sunyer, J. ;
Jarvis, D. ;
Svanes, C. ;
Gislason, T. ;
Heinrich, J. ;
Schouten, J. P. ;
Wjst, M. ;
Burney, P. ;
de Marco, R. .
THORAX, 2008, 63 (12) :1040-1045
[6]   Phenotype of Normal Spirometry in an Aging Population [J].
Fragoso, Carlos A. Vaz ;
McAvay, Gail ;
Van Ness, Peter H. ;
Casaburi, Richard ;
Jensen, Robert L. ;
MacIntyre, Neil ;
Gill, Thomas M. ;
Yaggi, H. Klar ;
Concato, John .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 192 (07) :817-825
[7]   Respiratory impairment and COPD hospitalisation in older persons: a competing risk analysis [J].
Fragoso, Carlos A. Vaz ;
Concato, John ;
McAvay, Gail ;
Van Ness, Peter H. ;
Gill, Thomas M. .
EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (01) :37-44
[8]   The Ratio of FEV1 to FVC as a Basis for Establishing Chronic Obstructive Pulmonary Disease [J].
Fragoso, Carlos A. Vaz ;
Concato, John ;
McAvay, Gail ;
Van Ness, Peter H. ;
Rochester, Carolyn L. ;
Yaggi, H. Klar ;
Gill, Thomas M. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (05) :446-451
[9]  
Global Initiative for Chronic Obstructive Lung Disease [webpage on the Internet], 2016, GLOBAL STRATEGY DIAG
[10]   Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use Data from the CanCOLD Study [J].
Labonte, Laura E. ;
Tan, Wan C. ;
Li, Pei Z. ;
Mancino, Palmina ;
Aaron, Shawn D. ;
Benedetti, Andrea ;
Chapman, Kenneth R. ;
Cowie, Robert ;
FitzGerald, J. Mark ;
Hernandez, Paul ;
Maltais, Francois ;
Marciniuk, Darcy D. ;
O'Donnell, Dennis ;
Sin, Don ;
Bourbeau, Jean .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 194 (03) :285-298